Troubleshoot Med Regimens for HFrEF

September 2024

Your problem-solving skills will be needed to fine-tune meds for heart failure with reduced ejection fraction (HFrEF).

Optimized regimens reduce risk of mortality and hospitalization.

But fewer than 1 in 6 patients get guideline-recommended “quad therapy” with an ACEI, ARB, or sacubitril/valsartan (Entresto)...an evidence-based beta-blocker (carvedilol, etc)...an aldosterone antagonist...plus an SGLT2 inhibitor (dapagliflozin, etc).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Immunizations Point Out Changes to Flu and COVID-19 Vaccines for 2024-2025
Hemorrhoids Guide Patients Through Hemorrhoid Treatments
COPD Watch for Ensifentrine (Ohtuvayre) for COPD
Pediatrics Educate Yourself on Back-to-School Rxs
Heart Failure Troubleshoot Med Regimens for HFrEF
Med Safety Stay Alert for Demo Meds That Look Like Actual Meds
Diabetes Know Key Updates for Management of Diabetic Ketoacidosis
NatMed Spotlight Be Prepared With Guidance About Elderberry

Troubleshoot Med Regimens for HFrEF

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents